BRAF V600E mutation
3 drugsBRAF V600E Oncogene Mutation
Predictive biomarker for patient selection in 9 indications
Understanding BRAF V600E mutation
What it means: V600E is the most common BRAF mutation, where valine is replaced by glutamic acid at position 600, causing pathway hyperactivation.
Why it matters: V600E is the primary target for BRAF inhibitors. V600K and other V600 mutations also respond to these drugs.
Testing: Tested via NGS, PCR-based assays, or V600E-specific IHC. Found in melanoma, colorectal, thyroid, and lung cancers.
3
Approved Drugs
9
Indications
2
Companies
BRAF V600E mutation is a precision-medicine biomarker linked to 3 FDA-approved targeted drugs from 2 companies, spanning 9 indications including Melanoma, Non-Small Cell Lung Cancer, Anaplastic Thyroid Cancer. Explore the targeted therapies, indications, testing methods, and companies developing BRAF V600E mutation drugs below.
Search BRAF V600E mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting BRAF V600E mutation
BRAF V600E mutation Indications
Melanoma Non-Small Cell Lung Cancer Anaplastic Thyroid Cancer Solid Tumors Low-Grade Glioma Head and Neck Cancer Squamous Cell Carcinoma of the Head and Neck Colorectal Cancer BRAF V600E Mutation-Positive Metastatic Colorectal Cancer